- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03029806
Déméthylase 1 spécifique à la lysine et sensibilité au sel chez l'homme
The purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure, focusing on the salt-sensitive regulatory enzyme Lysine-specific demethylase 1.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure in African American and Caucasians, focusing on the salt-sensitive regulatory enzyme Lysine-specific demethylase 1. This might help us understand why some people develop high blood pressure.
Healthy volunteers will be screened for eligibility and invited to participate in a 2 weeks study. Week 1 will be consumption of a low salt diet. Week 2 will be a high salt diet.
At the end of each week, participants will be admitted to a Clinical Research Center overnight and for one day.
On the CRC, participants will remain fasting and supine overnight and then next morning undergo hormonal and vascular testing. This will consist of blood drawing, echocardiogram, vascular tonometry, and assessment of renal blood flow before and after a low-dose Angiotensin II infusion.
The study outcome will compare how variants in the LSD1 gene affect hormonal and vascular responses according to race. This information will help us determine why some races and genetic profiles are more susceptible to detrimental effects of salt in the diet while others are protected against these effects.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Brigham and Women's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 25-45 years
- Caucasian or African American
- No gender preference (anticipate 50% female)
- Normotensive (screening blood pressure <140/90 mmHg)
- No history of hypertension, diabetes, stroke, coronary artery disease, kidney disease, cancer, thyroid disease, preeclampsia, or hospitalizations in 6 months
- Normal screening laboratory values (CMP, TSH, A1c)
- Normal ECG
- BMI <25 kg/m2
Exclusion Criteria:
- Pregnancy
- Breast feeding
- Any medication or herbal preparation
- >6oz alcohol/week
- Tobacco use
- Illicit drug use
- Chronic NSAID use
- Recent steroid use (injected, inhaled, oral)
- Decongestant use in the past 2 weeks
- Known sensitivity to infused Angiotensin II or para-amino hippurate
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Afr-Amer risk allele
African Americans carrying the LSD1 affected allele |
Change in aldosterone from baseline to after Ang II infusion on a LS diet Change in renal blood flow: High salt to low salt diet Change in vascular stiffness, baseline compared to AngII |
|
Comparateur placebo: Cauc risk allele
Caucasians carrying the LSD1 affected allele |
Change in aldosterone from baseline to after Ang II infusion on a LS diet Change in renal blood flow: High salt to low salt diet Change in vascular stiffness, baseline compared to AngII |
|
Comparateur placebo: Afr-Amer non-risk allele
African Americans carrying the LSD1 non-risk allele |
Change in aldosterone from baseline to after Ang II infusion on a LS diet Change in renal blood flow: High salt to low salt diet Change in vascular stiffness, baseline compared to AngII |
|
Comparateur placebo: Cauc non-risk allele
Caucasians carrying the LSD1 non-risk allele |
Change in aldosterone from baseline to after Ang II infusion on a LS diet Change in renal blood flow: High salt to low salt diet Change in vascular stiffness, baseline compared to AngII |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Aldosterone response to angiotensin II
Délai: After 1 week dietary salt manipulation
|
Change in aldosterone, baseline to after angiotensin II by genotype/race |
After 1 week dietary salt manipulation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Renal blood flow response to dietary salt
Délai: After 1 week dietary salt manipulation on both diets
|
Change in renal blood flow, high salt diet to low salt diet by genotype/race |
After 1 week dietary salt manipulation on both diets
|
|
Vascular stiffness response to angiotensin II
Délai: After 1 week dietary salt manipulation
|
Change in vascular stiffness, baseline to after angiotensin II by genotype/race |
After 1 week dietary salt manipulation
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Krug AW, Tille E, Sun B, Pojoga L, Williams J, Chamarthi B, Lichtman AH, Hopkins PN, Adler GK, Williams GH. Lysine-specific demethylase-1 modifies the age effect on blood pressure sensitivity to dietary salt intake. Age (Dordr). 2013 Oct;35(5):1809-20. doi: 10.1007/s11357-012-9480-0. Epub 2012 Oct 2.
- Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R, Leonor T, Cui J, Guo X, Taylor KD, Ida Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Shi Y. Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension. Am J Hypertens. 2012 Jul;25(7):812-7. doi: 10.1038/ajh.2012.43. Epub 2012 Apr 26.
- Pojoga LH, Williams JS, Yao TM, Kumar A, Raffetto JD, do Nascimento GR, Reslan OM, Adler GK, Williams GH, Shi Y, Khalil RA. Histone demethylase LSD1 deficiency during high-salt diet is associated with enhanced vascular contraction, altered NO-cGMP relaxation pathway, and hypertension. Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H1862-71. doi: 10.1152/ajpheart.00513.2011. Epub 2011 Aug 26.
- Heydarpour M, Parksook WW, Pojoga LH, Williams GH, Williams JS. Mineralocorticoid Receptor and Aldosterone: Interaction Between NR3C2 Genetic Variants, Sex, and Age in a Mixed Cohort. J Clin Endocrinol Metab. 2024 Dec 18;110(1):e140-e149. doi: 10.1210/clinem/dgae127.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2015P002540
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IPD will be shared first thru the publication of research results in peer-review scientific journals by the study investigator. IPD will be made available upon reasonable request from bona fide research organizations in an effort to provide broader impact and enrich public health knowledge. Research volunteer PHI will not be shared, and all participant data will be de-identified and coded. Only encrypted and secure network exchanges will be used for data transfer. Cost sharing my be required in order prepare datasets.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .